Valeritas May Improve Glycemic Control And Reduce Total Daily Insulin Dose For Patients With Type 2 Diabetes

Valeritas, makers of the V-Go insulin delivery device, today announced new findings from a planned interim analysis of data from the SIMPLE study that suggests that patients with Type 2 diabetes who switched to the V-Go insulin delivery device from their previous baseline treatment experienced improved glycaemic control and a reduction in total daily insulin dose with no significant change in weight.

Additionally, an independent and separate report conducted by clinicians at the Diabetes Centre of Excellence at the University of Massachusetts Medical School, suggests improvement in glycaemic control and a reduction in total daily insulin dose for patients requiring insulin who switched to the V-Go device.

Both sets of data were presented at the American Diabetes Association’s 73rd Scientific Sessions.1, 2

V-Go is a simple, fully-disposable device that delivers a continuous pre-set basal rate of insulin for 24 hours with on-demand mealtime dosing. It is designed to be easier to use and assist with blood glucose control in adult patients who require insulin.

“Like all diabetes providers, we see many patients in our diabetes clinic who are not achieving recognized treatment goals. We strive to understand the barriers that limit each patient’s treatment, in an effort to help such patients improve their outcomes. Not too surprisingly, we have identified many different factors that contribute to the less than ideal treatment metrics including busy work schedules, forgetfulness, needle phobia, inconvenience, and simply not fully embracing their disease,” said David M. Harlan, M.D., Co-Director of the Diabetes Centre of Excellence at the University of Massachusetts Medical School. “We saw the potential for the V-Go to help such patients and have been using the V-Go with increasing frequency. We’ve been very pleased with our patients’ early results. V-Go has been well accepted by most patients, and they’ve achieved improved glycaemic control.”

The SIMPLE study, “Effectiveness of V-Go for Patients with Diabetes in a Real-world Setting: A Long-term, Prospective, Observational Registry,” compares changes in baseline and endpoint A1C measures and observes glycaemic control, insulin dose requirements and other parameters. The study enrolled patients with Type 2 diabetes and a baseline A1C greater than 7 per cent. Study participants are switched from one of five baseline treatments to the V-Go for their basal and mealtime insulin delivery.1

“We are very encouraged by the consistency in results between our SIMPLE study and the independent University of Massachusetts experience,” said Kristine Peterson, Valeritas Chief Executive Officer. “Both analyses indicate that V-Go helps patients with Type 2 diabetes better manage their blood glucose, with a potential reduction in total insulin dose.”


on Twitter, 'LIKE' us on Facebook

FROM THIS SECTION

Be first to comment

Leave a Reply